35,501 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Aquatic Capital Management LLC

Aquatic Capital Management LLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 35,501 shares of the biopharmaceutical company's stock, valued at approximately $1,697,000.

A number of other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Halozyme Therapeutics by 0.6% during the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock worth $1,688,000 after acquiring an additional 200 shares during the last quarter. CreativeOne Wealth LLC lifted its stake in shares of Halozyme Therapeutics by 1.6% in the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 294 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 302 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $0.84 during trading hours on Monday, hitting $60.35. The stock had a trading volume of 196,520 shares, compared to its average volume of 1,418,957. The stock's fifty day simple moving average is $60.79 and its 200 day simple moving average is $55.41. The firm has a market capitalization of $7.46 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.42 and a beta of 1.26. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 1-year low of $40.19 and a 1-year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on HALO shares. Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Benchmark reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Finally, Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $62.89.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares of the company's stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,697 shares of company stock worth $1,276,552. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.